133 related articles for article (PubMed ID: 15371106)
21. Preclinical & pharmaceutical testing of liposomal amphotericin B.
Gokhale PC; Kotwani RN; Dange SY; Kshirsagar NA; Pandya SK
Indian J Med Res; 1993 Apr; 98():75-8. PubMed ID: 8344735
[TBL] [Abstract][Full Text] [Related]
22. Liposomal and lipid-based formulations of amphotericin B.
de Marie S
Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
[TBL] [Abstract][Full Text] [Related]
23. Physicochemical properties of amphotericin B liposomes prepared by reverse-phase evaporation method.
Rojanapanthu P; Sarisuta N; Chaturon K; Kraisintu K
Drug Dev Ind Pharm; 2003 Jan; 29(1):31-7. PubMed ID: 12602490
[TBL] [Abstract][Full Text] [Related]
24. Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: development, in vitro characterization and antioxidant activity.
Ourique AF; Chaves Pdos S; Souto GD; Pohlmann AR; Guterres SS; Beck RC
Eur J Pharm Sci; 2014 Dec; 65():174-82. PubMed ID: 25263567
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
26. Preparation, Statistical Optimization and
Mehrabani Yeganeh E; Bagheri H; Mahjub R
Iran J Pharm Res; 2020; 19(3):45-62. PubMed ID: 33680009
[TBL] [Abstract][Full Text] [Related]
27. Liposomal formulations of amphotericin B: differences according to the scientific evidence.
Azanza JR; Sádada B; Reis J
Rev Esp Quimioter; 2015 Dec; 28(6):275-81. PubMed ID: 26621170
[TBL] [Abstract][Full Text] [Related]
28. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
29. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
30. Amphotericin B liposomal formulation: applicable preparation methods, challenges, and tips.
Seify R; Zahednezhad F; Zakeri-Milani P; Valizadeh H
Drug Dev Ind Pharm; 2023 Dec; 49(5):367-376. PubMed ID: 37249553
[TBL] [Abstract][Full Text] [Related]
31. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
[TBL] [Abstract][Full Text] [Related]
32. Amphotericin B formulations and drug targeting.
Torrado JJ; Espada R; Ballesteros MP; Torrado-Santiago S
J Pharm Sci; 2008 Jul; 97(7):2405-25. PubMed ID: 17893903
[TBL] [Abstract][Full Text] [Related]
33. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
Bhatia A; Kumar R; Katare OP
J Pharm Pharm Sci; 2004 Jul; 7(2):252-9. PubMed ID: 15367383
[TBL] [Abstract][Full Text] [Related]
34. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
36. AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy.
Takemoto K; Kanazawa K
J Liposome Res; 2017 Sep; 27(3):186-194. PubMed ID: 27328721
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.
Juliano RL; Grant CW; Barber KR; Kalp MA
Mol Pharmacol; 1987 Jan; 31(1):1-11. PubMed ID: 3807887
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and tolerance of liposomal amphotericin B in patients.
Gokhale PC; Barapatre RJ; Advani SH; Kshirsagar NA; Pandya SK
J Antimicrob Chemother; 1993 Jul; 32(1):133-9. PubMed ID: 8226404
[TBL] [Abstract][Full Text] [Related]
39. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
Azanza Perea JR; Barberán J
Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
[TBL] [Abstract][Full Text] [Related]
40. Critical process parameters in manufacturing of liposomal formulations of amphotericin B.
Rivnay B; Wakim J; Avery K; Petrochenko P; Myung JH; Kozak D; Yoon S; Landrau N; Nivorozhkin A
Int J Pharm; 2019 Jun; 565():447-457. PubMed ID: 31071418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
